Mizuho reiterated an Outperform rating and $45 price target on Enliven (ELVN) after Merck (MRK) noted during its Q1 call that it believes Terns’ (TERN) TERN-701 major molecular response “will be north of 50% and within the confidence interval as had been publicly stated.” The firm said the comments are a positive for ELVN-001, noting that today’s “high-level quantification” only further supports the significant degradation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven price target raised to $55 from $36 at Clear Street
- Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
- Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
- Enliven rises 11.0%
- Enliven price target raised to $56 from $48 at H.C. Wainwright